Objectives: To develop a mechanism based pharmacokinetic (PK) and pharmacodynamic (PD) model of human granulocyte-colony stimulating factor (G-CSF), that would…
Read morePoster: Applications- Biologicals/vaccines
Pharmacodynamic Modelling of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects
Objectives: To evaluate the effect of rHu-EPO on reticulocyte production rate and age distribution in healthy subjects. Methods: Four pharmacokinetic…
Read moreBioequivalence study of a C1-esterase-inhibitor product (Cetor®) with optimised sampling design
Objectives: Cetor is a concentrate of a highly purified C1-inhibitor concentrate prepared from human fresh frozen plasma, used in the…
Read morePopulation modeling of the relationship between TACI Ig exposure and biomarker response in patients with rheumatoid arthritis (RA)
PDF of posterBackground: TACI‑Ig, a recombinant fusion protein containing the extracellular, ligand-binding portion of the receptor TACI, acts as an…
Read moreExposure-Response Modeling of the ACR20 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol.
Objectives: This analysis aimed to describe the exposure-response relationship of certolizumab pegol (CZP) in patients with rheumatoid arthritis, using the…
Read moreExposure-Response Modeling of the ACR50 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol.
Objectives: To describe the effect of exposure to certolizumab pegol (CZP) on the ACR20 [1] and ACR50 (American College of…
Read moreExposure-response analysis of certolizumab pegol in Crohn’s disease population
Objectives: The objectives of this population analysis were to: 1) characterize the placebo and drug effect of certolizumab pegol (CZP)…
Read moreApplication of mechanism-based population PKPD modelling in the rational selection of clinical candidates: an anti-IgE antibody example.
Objectives: Design, selection and development of clinical candidates should, optimally, incorporate mechanistic PKPD knowledge gained from previous experience with the…
Read moreRelationship Between Serum Concentration of the Interleukin-6 Receptor Inhibitor, Tocilizumab (TCZ), and Disease Activity Score (DAS28) in Patients with Rheumatoid Arthritis
Objective: To describe the relationship between tocilizumab concentration and the clinical endpoint (DAS28). A secondary objective was to investigate potential…
Read moreGranulocyte Colony Stimulating Factor Pharmacokinetics After Single and Repeated Administration of Several Doses.
Objectives: Granulocyte Colony Stimulating Factor (G-CSF) pharmacokinetics have a non linear dose and time dependent behavior, with its observed concentration-time…
Read more